Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer

BACKGROUND: Bevacizumab and erlotinib have been demonstrated to prolong overall survival in patients with non-squamous non-small cell lung cancer (NSCLC). We designed a four-arm Phase III trial to evaluate the efficacy and toxicity of the combination of docetaxel, carboplatin, bevacizumab, and erlot...

Descripción completa

Detalles Bibliográficos
Autores principales: Boutsikou, Eftimia, Kontakiotis, Theodoros, Zarogoulidis, Paul, Darwiche, Kaid, Eleptheriadou, Ellada, Porpodis, Konstantinos, Galaktidou, Grammati, Sakkas, Leonidas, Hohenforst-Schmidt, Wolfgang, Tsakiridis, Kosmas, Karaiskos, Theodoros, Zarogoulidis, Konstantinos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589083/
https://www.ncbi.nlm.nih.gov/pubmed/23467839
http://dx.doi.org/10.2147/OTT.S42245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589083/
https://www.ncbi.nlm.nih.gov/pubmed/23467839
http://dx.doi.org/10.2147/OTT.S42245

Ejemplares similares